BioLine Rx Ltd ADR BLRX
News
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
